Steroids. CLXXXIV. 2-Formyl- Δ^2 -androstenes and Related Compounds. A New Class of Potent Anabolic Agents

J. C. ORR, O. HALPERN, AND A. BOWERS

Research Laboratories, Syntex, S.A., Apartado Postal 2679, Mexico, D.F., Mexico
Received October 28, 1961

Recent work has demonstrated that the absence of the C-3-oxygen atom in certain androstane derivatives is still compatible with high progestational²⁻⁴ or anabolic-androgenic⁴⁻⁸ activities.

Further studies of compounds with variable electron density patterns around ring $A^{7,8}$ led us to investigate the 2-formyl- Δ^2 -system. Certain compounds of this type were found to have very high myotrophic activities with low androgenicity.

Sodium borohydride reduction of 2-methoxymethylene-androstane-17 β -ol-3-one⁵ (Ia) afforded the corresponding 3β -alcohol (Ib) (m.p. 158–160° $[\alpha]_D$ $-35^\circ)^{9,10}$ which upon acid treatment afforded 2-formyl- Δ^2 -androstene-17 β -ol (IIa) (m.p. 196–198°, $[\alpha]_D$ +107°, $\lambda_{\max}^{\text{EtOH}}$ 232 m μ , log ϵ 4.14, $\lambda_{\max}^{\text{KBr}}$ 1663, 1645 cm.⁻¹); characterized as its acetate (IIb) (m.p. 161–163°, $[\alpha]_D$ +84°), and cyclopentylpropionate (IIe) (m.p. 138–141°, $[\alpha]_D$ +75°). A similar reaction sequence from 17 α -methyl-2-methoxymethylene-androstane-17 β -ol-3-one (m.p. 190–192°, $[\alpha]_D$ +20°), prepared by acid catalyzed methylation of 2-hydroxymethylene-17 α -methyl-androstane-17 β -ol-3-one⁵ in methanol led to 17 α -methyl-2-formyl- Δ^2 -androstene-17 β -ol (IId) (m.p. 138–140°; $[\alpha]_D$ +70°, $\lambda_{\max}^{\text{EtOH}}$ 232 m μ , log ϵ 4.11).

Sodium borohydride reduction of IIa and IId led, respectively, to the corresponding 2-hydroxymethyl- Δ^2 analogs (IIe) (m.p. 190–192°,

⁽¹⁾ Part CLXXXIII. J. A. Zderic, O. Halpern, H. Carpio, A. Ruiz, I. Delfin, D. Chávez Limón, H. Jiménez, A. Bowers and H. J. Ringold, J. Org. Chem., in press.

⁽²⁾ M. S. de Winter, C. M. Siegmann and S. A. Szpilfogel, Chem. and Ind., 905 (1959).

⁽³⁾ N. E. Borglin, Acta Endocrinologica, Supplementum LVIII (1960).

⁽⁴⁾ R. O. Clinton, A. J. Manson, F. W. Stonner, R. G. Christiansen, A. L. Beyler, G. O. Potts and A. Arnold, J. Org. Chem., 26, 279 (1961).

⁽⁵⁾ R. O. Clinton, A. J. Manson, F. W. Stonner, A. L. Beyler, G. O. Potts and A. Arnold, J. Am. Chem. Soc., 81, 1513 (1959); R. O. Clinton et al., ibid., 83, 1478 (1961).

⁽⁶⁾ J. A. Zderic, O. Halpern, H. Carpio, A. Ruiz, D. C. Limón, L. Magaña, H. Jiménez, A. Bowers and H. J. Ringold, *Chem. and Ind.*, 1625 (1960), and ref. 1.

⁽⁷⁾ J. A. Edwards and A. Bowers, ibid., in press.

⁽⁸⁾ A. D. Cross, J. A. Edwards and A. Bowers, J. Med. Pharm. Chem., 5, 406 (1962).

⁽⁹⁾ All rotations in chloroform.

⁽¹⁰⁾ All new compounds were analyzed satisfactorily for C, H and O.

 $[\alpha]_D + 58^\circ$) and IIf (m.p. 167–169°, $[\alpha]_D + 26^\circ$). Oxidation of IIe and IIf with dichlorodicyanobenzoquinone¹¹ regenerated IIa and IId in good yield whereas with 8 N chromic acid¹² IIb gave the corresponding carboxylic acid IIg (m.p. 267–268°, $[\alpha]_D + 66^\circ$ $\lambda_{\text{max}}^{\text{EtOH}}$ 218 m μ log ϵ 3.96).

IV

III

Both IIa and IId reacted with methylmagnesium bromide to afford the corresponding 2-(1'-hydroxyethyl)- Δ^2 analogs which underwent oxidation¹¹ to afford, respectively, 2-acetyl- Δ^2 -androstene-17 β -ol (IIh) (m.p. 213–215°, $[\alpha]_D$ +110°, $\lambda_{\max}^{\text{EtOH}}$ 234 m μ , log ϵ 4.02) and 17 α -methyl-2-acetyl- Δ^2 -androstene-17 β -ol (IIi) (m.p. 191–193°, $[\alpha]_D$ +88°, $\lambda_{\max}^{\text{EtOH}}$ 234 m μ log ϵ 4.05).

⁽¹¹⁾ D. Burn, V. Petrow and G. O. Weston, Tetrahedron Letters, No. 9, 14 (1960),

⁽¹²⁾ K. Bowden, I. M. Heilbron, E. R. H. Jones and B. C. L. Weedon, J. Chem. Soc., 39 (1946).

To investigate the effects of methyl and halogen substitution and further unsaturation to the 2-formyl- Δ^2 -system the 4α -methyl-, 4α chloro- and Δ^4 - analogs of IIa were prepared. 4α -Methylandrostane-17 β -ol-3-one¹³ (m.p. 197.5–200°, $[\alpha]_D$ +7°) was converted into 4α methyl-2-formyl- Δ^2 -androstene-17 β -ol (IIj) (m.p. 218–222°, $[\alpha]_D$ $+24^{\circ}$ (dioxane), $\lambda_{\text{max}}^{\text{EtoH}}$ 232 m μ , log ϵ 4.15) in the usual way via 4α methyl-2-methoxymethylene-androstane-17β-ol-3-one (Id) (m.p. 218-218.5°). Vigorous acetylation of IIa gave the enol acetate (III) (m.p. 113–116°, $[\alpha]_D$ +41°, $\lambda_{\max}^{\text{EtOH}}$ 248 m μ , $\log \epsilon$ 4.15) which upon treatment with N-chlorosuccinimide in acid solution gave 4α -chloro-2formyl- Δ^2 -androstene- 17β -ol acetate (IIk) (m.p. 206-207°, $[\alpha]_D$ -24° , $\lambda_{\text{max}}^{\text{EtOH}}$ 230–232 m μ , log ϵ 4.08). Similar treatment of III with N-bromosuccinimide followed by dehydrobromination with calcium carbonate in dimethylformamide 14 led to 2-formyl- $\Delta^{2,4}$ -androstadiene-17 β -ol acetate (IV) (m.p. 169-170°, [α]_D +129°, λ ^{EtOH}_{max} 320-322 μ m. log ϵ 4.17).

Details concerning the extension of this work to the progestational and cortical hormone areas will be described shortly.

Biological Activities.—In preliminary assays IIa (and its esters), IId, IIe and IIf all showed a favorable anabolic-androgenic ratio. Assays¹⁵ were carried out in the immature castrate male rat. The effect on the weight of the seminal vesicle and prostate was a measure of androgenicity and the effect on the levator ani muscle gave the myotrophic (anabolic) activity. By injection IIa and IIe both showed from 0.2 to 0.4 times the androgenicity and 3 to 5 times the anabolic activity of testosterone propionate. The duration of activity of IIa was considerably greater than that of testosterone propionate. Oral administration of IId showed that it had approximately 0.3 to 0.4 times the androgenicity and 3 times the anabolic activity of methyltestosterone.

Introduction of a chlorine atom or a methyl group at C-4 α or a Δ^4 -double bond did not enhance the activity of the parent compound.

⁽¹³⁾ H. J. Ringold and E. Necoechea, unpublished work. We wish to thank Dr. Ringold for the details concerning the preparation of this compound which involved a catalytic hydrogenation of 4-methyltestosterone followed by mild base treatment.

⁽¹⁴⁾ Cf. R. Joly, J. Warnant, et al., Bull. soc. chim. France, 366, 367 (1958).

⁽¹⁵⁾ We wish to thank Dr. Ralph Dorfman at the Worcester Foundation, Shrewsbury, Mass., and Endocrine Laboratories, Madison. Wisconsin, for the bioassays.